Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Acquisitions & Divestments: 2022-2025

Historic Change in Acquisitions & Divestments for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $64.0 million.

  • Amylyx Pharmaceuticals' Change in Acquisitions & Divestments fell 14.67% to $64.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.0 million, marking a year-over-year decrease of 41.21%. This contributed to the annual value of $344.0 million for FY2024, which is 12.72% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Change in Acquisitions & Divestments stood at $64.0 million, which was up 3.23% from $62.0 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Acquisitions & Divestments registered a high of $147.9 million during Q4 2023, and its lowest value of $24.9 million during Q1 2022.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $66.0 million (2023), whereas its average is $84.0 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Change in Acquisitions & Divestments soared by 335.06% in 2023 and then tumbled by 56.06% in 2024.
  • Quarterly analysis of 4 years shows Amylyx Pharmaceuticals' Change in Acquisitions & Divestments stood at $34.0 million in 2022, then surged by 335.06% to $147.9 million in 2023, then plummeted by 56.06% to $65.0 million in 2024, then dropped by 14.67% to $64.0 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $64.0 million for Q3 2025, versus $62.0 million for Q2 2025 and $60.0 million for Q1 2025.